$ News

OptiNose (OPTN) Reports Q4 Loss, Tops Revenue Estimates

OptiNose: Q4 Earnings Snapshot

Optinose Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights

Wall Street Analysts Believe OptiNose (OPTN) Could Rally 143.06%: Here's is How to Trade

OPTN Stock Soars 53% on Inking $330M Deal to be Acquired by Paratek

Why OptiNose Inc. (OPTN) Surged On Thursday?

OptiNose Surges Premarket Following Acquisition Agreement With Paratek Pharmaceuticals for Up to $330 Million

Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call

OptiNose (NASDAQ:OPTN) shareholders have endured a 90% loss from investing in the stock five years ago

Optinose Announces Reporting Date for Fourth Quarter and Full Year 2024 Financial Results

Optinose price target adjusted for stock split at Lake Street

Optinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22.4 Million

Optinose Announces 1-for-15 Reverse Stock Split

Optinose to Present at the Piper Sandler 36th Annual Healthcare Conference

OptiNose, Inc. (NASDAQ:OPTN) Just Reported, And Analysts Assigned A US$3.50 Price Target

OptiNose Third Quarter 2024 Earnings: EPS: US$0.002 (vs US$0.083 loss in 3Q 2023)

OptiNose Inc (OPTN) Q3 2024 Earnings Call Highlights: Revenue Growth Amid Revised Guidance

Q3 2024 OptiNose Inc Earnings Call

OptiNose (OPTN) Reports Break-Even Earnings for Q3

OptiNose, Inc. (OPTN) Q3 2024 Earnings Call Transcript